A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma
The results of the PERSEUS study showed that including daratumumab in D-VRd induction/consolidation and D-R maintenance was better for treating multiple myeloma than the current standard VRd treatment followed by R maintenance alone in adults with a new diagnosis of multiple myeloma who were also able to receive an autologous stem cell transplant. Of importance, there were no unexpected side effects in either group.<b>Clinical Trial Registration:</b> NCT02874742 (GRIFFIN) (ClinicalTrials.gov).
Authors
- Andrew Spencer (ORCID: https://orcid.org/0000-0002-0531-7424)
- Pieter Sonneveld (ORCID: https://orcid.org/0000-0002-0808-2237)
- Roberto Mina (ORCID: https://orcid.org/0000-0002-8144-541X)
- P. Joy Ho (ORCID: https://orcid.org/0000-0002-2811-8671)
- Wilfried W. H. Roeloffzen (ORCID: https://orcid.org/0000-0003-3976-8001)
- Véronique Vanquickelberghe
- Hermann Einsele (ORCID: https://orcid.org/0000-0002-7680-0819)
- Mario Boccadoro (ORCID: https://orcid.org/0000-0001-8130-5209)
- Francesca Gay (ORCID: https://orcid.org/0000-0002-8619-412X)
- Niels W.C.J. van de Donk (ORCID: https://orcid.org/0000-0002-7445-2603)
- Meletios Athanasios Dimopoulos (ORCID: https://orcid.org/0000-0001-8990-3254)
- Joan Bladé
- Eirini Katodritou (ORCID: https://orcid.org/0000-0001-9404-807X)
- Silvia Mangiacavalli (ORCID: https://orcid.org/0000-0001-9787-3083)
- Artur Jurczyszyn (ORCID: https://orcid.org/0000-0001-9796-8365)
- Sarah Lonergan
- Xavier P Leleu (ORCID: https://orcid.org/0000-0002-9822-4170)
- Diego Vieyra
- Richard G. Carson (ORCID: https://orcid.org/0000-0002-1190-2814)
- Emilie M.J. van Brummelen (ORCID: https://orcid.org/0000-0002-6526-4790)
- Annemiek Broijl (ORCID: https://orcid.org/0000-0002-0554-8003)
- Annette Juul Vangsted (ORCID: https://orcid.org/0000-0002-2131-731X)
- Michèle Cavo (ORCID: https://orcid.org/0000-0003-4514-3227)
- Elisabetta Antonioli (ORCID: https://orcid.org/0000-0001-5547-3516)
- Angelo Belotti (ORCID: https://orcid.org/0000-0002-0617-3127)
- Tobias Silzle (ORCID: https://orcid.org/0000-0001-6859-3090)
- Tahamtan Ahmadi (ORCID: https://orcid.org/0009-0007-5031-3792)
- Anna Sureda (ORCID: https://orcid.org/0000-0002-1238-6970)
- Anna Sitthi-Amorn (ORCID: https://orcid.org/0000-0002-4745-6801)
- Fredrik Schjesvold (ORCID: https://orcid.org/0000-0003-1096-0569)
- Meral Beksaç (ORCID: https://orcid.org/0000-0003-1797-8657)
- Paula Rodríguez‐Otero (ORCID: https://orcid.org/0000-0001-5236-7785)
- Aurore Perrot (ORCID: https://orcid.org/0000-0003-0131-8689)
- Cyrille Hulin (ORCID: https://orcid.org/0000-0002-3749-5161)
- Roman Hájek (ORCID: https://orcid.org/0000-0001-6955-6267)
- Hang Quach (ORCID: https://orcid.org/0000-0002-4796-3352)
- Jianping Wang (ORCID: https://orcid.org/0000-0002-7522-7539)
- Michel Delforge (ORCID: https://orcid.org/0000-0002-0147-2291)
- Laura Rosiñol
- Philippe Moreau (ORCID: https://orcid.org/0000-0003-1780-8746)
- Yanfang Liu (ORCID: https://orcid.org/0009-0001-5025-7459)
- Carla J. de Boer
Institutions
- Jagiellonian University (PL)
- Oslo University Hospital (NO)
- The University of Sydney (AU)
- University Medical Center Groningen (NL)
- Université Toulouse III - Paul Sabatier (FR)
- Janssen (Belgium) (BE)
- Ankara University (TR)
- Inserm (FR)
- The University of Melbourne (AU)
- Université Fédérale de Toulouse Midi-Pyrénées (FR)
- University of Oslo (NO)
- University of Ostrava (CZ)
- National and Kapodistrian University of Athens (GR)
- University of St.Gallen (CH)
- Genmab (United States) (US)
- Royal Prince Alfred Hospital (AU)
- Rigshospitalet (DK)
- Centre Hospitalier Universitaire de Toulouse (FR)
- Université de Poitiers (FR)
- Fundación Pethema (ES)
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- Institut d'Investigació Biomédica de Bellvitge (ES)
- St Vincent's Hospital Melbourne (AU)
- Theageneio General Hospital (GR)
- University Hospital Ostrava (CZ)
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- Institut Català d'Oncologia (ES)
- Hospital Clínic de Barcelona (ES)
- Hôpital Cardiologique du Haut-Lévêque (FR)
- Universitätsklinikum Würzburg (DE)
- Clinica Universidad de Navarra (ES)
- Erasmus MC Cancer Institute (NL)
- Janssen (United States) (US)
- Policlinico San Matteo Fondazione (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Janssen (Netherlands) (NL)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Alfred Health (AU)
- University of Florence (IT)
- Monash University (AU)
- Universitat de Barcelona (ES)
- Vrije Universiteit Amsterdam (NL)
- University of Bologna (IT)
- KU Leuven (BE)
Publication Details
- Journal
- Future Oncology
- Published
- 2024-09-17
- DOI
- https://doi.org/10.1080/14796694.2024.2394323
- Citations
- 2
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.91
Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- Sanofi
- Celgene
- Karyopharm Therapeutics
- Regeneron Pharmaceuticals
- AbbVie Biotherapeutics
- Sanofi Pasteur
- Janssen Biotech
- Janssen Pharmaceuticals